Want to see TECH full AI Analyst Report?
EarningsQ3 2026 Earnings Report
TECH Q3 2026 EPS Results
Actual EPS$0.53
Consensus EPS$0.53
Beat/MissMissed by -<$0.01
One Year Ago EPS$0.56
TECH Q3 2026 Revenue Results
Actual Revenue$311.42M
Expected Revenue$316.11M
Beat/MissMissed by -$4.69M
YoY Revenue Growth-1.51%
Earnings Announcement Details
QuarterQ3 2026
Date05/06/2026
TimeBefore Open
Conference CallWednesday, May 6, 2026
TECH Upcoming Earnings
Bio-Techne's next earnings date is estimated for November 3, 2026, based on past reporting schedules.
Q3 2026 Earnings Call Audio
TECH Q3 2026 Earnings Call
0:00 / 0:00
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlighted strong execution in high-value growth vectors (Spatial Biology/COMET, GMP proteins excl. timing impacts, Proteomic Analysis instruments, large pharma strength and four consecutive quarters of China growth), solid sequential margin improvement and robust cash generation. Offsetting these positives were a 2% organic revenue decline, continued weakness in emerging/early-stage biotech spending, timing headwinds from two fast-track cell therapy customers and an OEM order, and YoY mix-related margin pressure. Management expects near-term organic revenue to be roughly flat but positions the business for an inflection in fiscal 2027 as funding improvements translate to customer spending.Company Guidance
Strong Spatial Biology Momentum and COMET Backlog
Spatial Biology delivered mid-teens growth overall with the COMET Multiomic Spatial Platform growing more than 65% in the quarter; company exited the quarter with a record COMET backlog and installed the first COMET system in China, positioning the platform for continued scaling.
GMP Protein Growth (Excluding Fast-Track Customers)
GMP protein portfolio grew nearly 50% year-over-year when excluding the two fast-track cell therapy customers that created timing effects, underscoring strong demand from advancing cell therapy programs.
Proteomic Analysis Strength and Regulatory Milestone
Proteomic Analysis instruments delivered mid-single-digit growth supported by favorable instrument placements and utilization; Ella platform showed strong adoption (3-year neurology assay portfolio CAGR of 50%) and achieved CE-IVD marking enabling clinical use in Europe.
Large Pharma and China End-Market Strength
Large pharmaceutical customers delivered their sixth consecutive quarter of double-digit growth; China achieved positive organic growth for the fourth consecutive quarter (low single-digit growth), with increasing demand from biopharma and CRO/CDMO customers focused on ADCs, cell therapy and autoimmune disorders.
Profitability and Margin Expansion (Sequential)
Adjusted operating margin was 34.2% in Q3, representing a 310 basis point sequential improvement over fiscal Q2; adjusted gross margin improved sequentially by 190 basis points to 70.4%.
Solid Cash Generation and Strong Balance Sheet
Generated $86.7 million in operating cash flow in Q3, with $9.1 million in net capital expenditures; ended the quarter with $209.8 million in cash and bank debt of $200 million, and total leverage below 1x EBITDA.
Reported EPS and GAAP Improvement
Adjusted EPS was $0.53 (down $0.03 year-over-year) while GAAP EPS improved to $0.32 from $0.14 in the prior year period, reflecting improved GAAP profitability despite some mix headwinds.
Strategic Portfolio Simplification and AI Integration
Announced strategic brand alignment consolidating 10 brands into 3 (R&D Systems, Bio-Techne Spatial Biology, Bio-Techne Diagnostics) to simplify customer engagement; investing AI internally to design novel proteins using five decades of proprietary data, and positioning Bio‑Techne as a data provider supporting AI-driven discovery.
TECH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed